Gene expression profiles following intracoronary injection of mesenchymal stromal cells using a porcine model of chronic myocardial infarction

Cytotherapy

Volumn 13, Issue 4, 2011, Pages 407-418

  Barallobre Barreiro, Javier ^a   De Il Áaduya, Óskar Martínez ^a,b   Moscoso, Isabel ^a   Calvi Ñ O Santos, Ramón ^c   Aldama, Guillermo ^c   Centeno, Alberto ^d   López Pelaez, Eduardo ^d   Doménech, Nieves ^a,d  

^a Unidad de Investigación   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c Unidad de Hemodinámica   (Spain)

^d Osteoarticular and Aging Research Lab   (Spain)

Author keywords

cell transplantation; gene expression; mesenchymal stromal cells; pig

Indexed keywords

AZACITIDINE; CHEMOKINE RECEPTOR CXCR4; MYOCYTE ENHANCER FACTOR 2; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR NKX2.5;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HEART ATRIUM; HEART DEVELOPMENT; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART VENTRICLE; HEART VENTRICLE SEPTUM; IMMUNOHISTOCHEMISTRY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STEM CELL MOBILIZATION; SWINE; THERAPY EFFECT;

EID: 79952663268     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2010.529892     Document Type: Article

References (46)

1. Laflamme MA, Murry CE. Regenerating the heart. Nat Biotechnol. 2005;23:845-56. (Pubitemid 43093128)
2. Chatterjee K, Rame JE. Systolic heart failure: chronic and acute syndromes. Crit Care Med. 2008;36:44-51.
3. Segers VF, Lee RT. Stem-cell therapy for cardiac disease. Nature. 2008;451:937-42. (Pubitemid 351301749)
4. Psaltis PJ, Zannettino AC, Worthley SG, Gronthos S. Concise review. Mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells. 2008;26:2201-10.
5. Sotiropoulou PA, Papamichail M. Immune properties of mes-enchymal stem cells. Methods Mol Biol. 2007;407:225-43.
6. Chen S, Liu Z, Tian N, Zhang J, Yei F, Duan B, et al. Intra-coronary transplantation of autologous bone marrow mesen-chymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol. 2006;18:552-6. (Pubitemid 44704523)
7. Shi RZ, Li QP. Improving outcome of transplanted mesen-chymal stem cells for ischemic heart disease. Biochem Biophys Res Commun. 2008;376:247-50.
8. Reffelmann T, Kloner RA. Intracoronary blood- or bone marrow-derived cell transplantation in patients with ischemic heart disease. Regen Med. 2009;4:709-19.
9. Nadal-Ginard B, Torella D, Ellison G. Cardiovascular regenerative medicine at the crossroads. Clinical trials of cellular therapy must now be based on reliable experimental data from animals with characteristics similar to humans. Rev Esp Cardiol. 2006;59:1175-89. (Pubitemid 46139214)
10. Hashemi SM, Ghods S, Kolodgie FD, Parcham-Azad K, Keane M, Hamamdzic D, et al. A placebo controlled, dose-ranging, safety study of allogenic mesenchymal stem cells injected by endomyocardial delivery after an acute myocardial infarction. Eur Heart J. 2008;29:251-9.
11. Bosch P, Pratt SL, Stice SL. Isolation, characterization, gene modification, and nuclear reprogramming of porcine mesenchymal stem cells. Biol Reprod. 2006;74:46-57. (Pubitemid 43068790)
12. Quevedo HC, Hatzistergos KE, Oskouei BN, Feigenbaum GS, Rodriguez JE, Valdes D, et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci USA. 2009;106:14022-7.
13. Ye NS, Zhang RL, Zhao YF, Feng X, Wang YM, Luo GA. Effect of 5-azacytidine on the protein expression of porcine bone marrow mesenchymal stem cells in vitro. Genom Proteom Bioinform. 2006;4:18-25.
14. Xu H, Baldini A. Genetic pathways to mammalian heart development: recent progress from manipulation of the mouse genome. Semin Cell Dev Biol. 2007;18:77-83. (Pubitemid 46330841)
15. 2 -ATPase of sarcoplasmic reticulum. Acta Biochimica Polonica. 2003; 50:337-65. (Pubitemid 37034690)
16. Baudino TA, Carver W, Giles W, Borg TK. Cardiac fibroblasts: friend or foe? Am J Physiol Heart Circ Physiol. 2006;291: 1015-26.
17. Black BL. Transcriptional pathways in second heart field development. Semin Cell Dev Biol. 2007;18:67-76. (Pubitemid 46343797)
18. Jamali M, Rogerson PJ, Wilton S, Skerjanc IS. Nkx2-5 activity is essential for cardiomyogenesis. J Biol Chem. 2001;276: 42252-8.
19. Peterkin T, Gibson A, Patient R. Redundancy and evolution of GATA factor requirements in development of the myocardium. Dev Biol. 2007;311:623-35. (Pubitemid 350064367)
20. Karamboulas C, Dakubo GD, Liu J, De Repentigny Y, Yutzey K, Wallace VA, et al. Disruption of MEF2 activity in cardiomyob-lasts inhibits cardiomyogenesis. J Cell Sci. 2006;119:4315-21. (Pubitemid 44774038)
21. Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation. 2004;110:3300-5. (Pubitemid 39557491)
22. Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia. 2006;20:1915-24. (Pubitemid 44614878)
23. Rönnstrand L. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci. 2004;61:2535-48. (Pubitemid 39586516)
24. Rajappa M, Sharma A. Biomarkers of cardiac injury: an update. Angiology. 2005;56:677-91. (Pubitemid 41790976)
25. Guide for the Care and Use of Laboratory Animals. National Academy of Sciences, Washington, 1996.
26. European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes. States of the Councilof Europe, Strasbourg, 1986.
27. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest. 1999;103:697-705. (Pubitemid 29122423)
28. Kraitchman DL, Heldman AW, Atalar E, Amado LC, Martin BJ, Pittenger MF, et al. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation. 2003;107:2290-3. (Pubitemid 36578497)
29. Reiber JH, Viddeleer AR, Koning G, Schalij MJ, Lange PE. Left ventricular regression equations from single plane cine and digital X-ray ventriculograms revisited. Int J Card Imaging. 1996;12:69-78. (Pubitemid 26280872)
30. Nygard AB, J ø rgensen CB, Cirera S, Fredholm M. Selection of reference genes for gene expression studies in pig tissues using SYBR green qPCR. BMC Mol Biol. 2007;8:67-72.
31. -AACt method. Methods. 2001;25:402-8. (Pubitemid 34164012)
32. Nassiri SM, Khaki Z, Soleimani M, Ahmadi SH, Jahanzad I, Rabbani S, et al. The similar effect of transplantation of marrow-derived mesenchymal stem cells with or without prior differentiation induction in experimental myocardial infarction. J Biomed Sci. 2007;14:745-55. (Pubitemid 47573152)
33. Bartunek J, Croissant JD, Wijns W, Gofflot S, de Lavareille A, Vanderheyden M, et al. Pretreatment of adult bone marrow mesenchymal stem cells with cardiomyogenic growth factors and repair of the chronically infarcted myocardium. Am J Physiol Heart Circ Physiol. 2007;292:1095-2004.
34. Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist. 2005;10:176-82. (Pubitemid 40463154)
35. Moscoso I, Centeno A, López E, Rodriguez-Barbosa JI, Santamarina I, Filgueira P, et al. Differentiation'in vitro'of primary and immortalized porcine mesenchymal stem cells into cardiomyocytes for cell transplantation. Transplant Proc. 2005;37:481-2. (Pubitemid 40459824)
36. Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabé-Heider F, Walsh S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324:98-102.
37. Martins AA, Paiva A, Morgado JM, Gomes A, Pais ML. Quantification and immunophenotypic characterization of bone marrow and umbilical cord blood mesenchymal stem cells by multicolor flow cytometry. Transplant Proc. 2009;41: 943-6.
38. Askari AT, Unzek S, Popovic ZB, Goldman CK, Forudi F, Kiedrowski M, et al. Effect of stromalcell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet. 2003;362:675-6.
39. Tang XL, Rokosh G, Sanganalmath SK, Yuan F, Sato H, Mu J, Dai S, et al. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation. 2010;121:293-305.
40. Torella D, Ellison GM, Karakikes I, Nadal-Ginard B. Resident cardiac stem cells. Cell Mol Life Sci. 2007;64: 661-73.
41. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-17.
42. Tallini YN, Greene KS, Craven M, Spealman A, Breitbach M, Smith J, et al. c-kit expression identifies cardiovascular precursors in the neonatal heart. Proc Natl Acad Sci USA. 2009;106:1808-13.
43. Zhao Q, Sun Y, Xia L, Chen A, Wang Z. Randomized study of mononuclear bone marrow cell transplantation in patients with coronary surgery. Ann Thorac Surg. 2008;86:1833-40.
44. Stamm C, Kleine HD, Choi YH, Dunkelmann S, Lauffs JA, Lorenzen B, et al. Imtramyocardial delivery of CD133 + bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardiovas Surg. 2007;133:717-25.
45. Boyle AJ, Whitbourn R, Schlicht S, Krum H, Kocher A, Nan-durkar H, et al. Intra-coronary high-dose CD34+ stem cells in patient with chronic ischemic heart disease: a 12-month follow-up. Int J Cardiol. 2006;109:21-7.
46. Bartunek J, Vanderheyden M, Vandekerckhove B, Mansour S, De Bruyne B, De Bondt P, et al. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infa rction: feasibility and safety. Circulation. 2005;112:1178-83.